https://www.selleckchem.com/pr....oducts/Nanchangmycin
Liver transplantation (LT) recipients such as all organ transplant recipients, have a risk of developing de novo malignancies owing to prolonged immunosuppression. However, there is limited data on this after living donor liver transplantation (LDLT), wherein immunosuppression levels are less than in deceased donor transplantation. We aim to describe experience of de novo malignancies from a predominantly LDLT center. A total of 2100 adults (age 18 years) who underwent LT between January 2006 and December 2017 were retrospecti
إعجاب
علق
شارك
